Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and non-pregnant, non-lactating females aged ≥ 40.~2. Patients with a clinical diagnosis of stable moderate to severe COPD, according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines: (http://www.goldcopd.com) and stable airway obstruction. Post-salbutamol FEV1/FVC \< 70% at Screening Visit (Visit 1) (i.e., 100xpost-salbutamol FEV1/FVC \<70%).~3. Current, or ex-cigarette smoker with a smoking history of at least 10 pack-years.~4. Patient whose FEV1 at the Screening Visit measured between 10-15 minutes post inhalation of salbutamol is 30% \< FEV1 \<80% of the predicted normal value (i.e., 100 x Post-salbutamol FEV1/ Predicted FEV1 must be \< 80% and ≥ 30%).~5. Female patients at least 1 year post-menopausal, surgically sterile (defined as having a hysterectomy or tubal ligation), or practicing a medically approved and highly effective method of contraception.~6. Patients who understand the study procedures and are willing to participate in the study as indicated by signing the informed consent.~Exclusion Criteria:~1. History or current diagnosis of asthma.~2. Clinically significant respiratory conditions other than COPD at the time of Inform Consent signature~3. Hospitalisation due to COPD exacerbation within the previous 3 months.~4. Signs of a COPD exacerbation or respiratory infection (including the upper respiratory tract) within the previous 6 weeks.~5. Clinically significant cardiovascular conditions~6. Presence of symptomatic prostatic hypertrophy and/or bladder neck obstruction.~7. Presence of narrow-angle glaucoma.~8. QTcB) above 470 milliseconds in the ECG performed at Screening Visit,~9. Patient who does not maintain regular day/night, waking/sleeping cycles

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium bromide 100 μg bid (Type: EXPERIMENTAL): Aclidininum bromide 100 μg twice daily by inhalation
- Aclidininum bromide 200 μg bid (Type: EXPERIMENTAL): Aclidininum bromide 200 μg twice daily by inhalation
- Aclidininum bromide 400 μg bid (Type: EXPERIMENTAL): Aclidininum bromide 400 μg twice daily by inhalation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice-daily by inhalation
- Formoterol 12 μg bid (Type: ACTIVE_COMPARATOR): Formoterol 12 μg twice daily by inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).